Search
Filter Results
Displaying 311–320 of 585 for “Retinitis pigmentosa”
-
May 14, 2021
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
-
May 10, 2021
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
May 10, 2021
Research NewsPrecise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
May 5, 2021
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
May 3, 2021
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Research NewsCellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Apr 26, 2021
SparingVision to Acquire Therapy for Resurrecting Dormant Cones for Vision Restoration
Research NewsThe gene-agnostic approach shows promise for people with late-stage RP and related diseases.
-
Apr 26, 2021
Ambitious Swimmer Spreading Optimism
Beacon Stories26-year-old Becca is a two-time Paralympic swimmer for Team USA, diagnosed with Usher syndrome type 1 (USH1) at only four years old. But she has never let her diagnosis with Usher syndrome stop her from doing exactly what she puts her mind to.
-
Apr 14, 2021
Beacon StoriesAmerican Banker dubbed her as “the sharpest mind analyzing banking policy today – maybe ever.”
-
Mar 30, 2021
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
Research NewsThe approach holds potential for restoring vision to people with little or no vision
-
Mar 24, 2021
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
Research NewsThe company is planning two Phase 2/3 clinical trials for the treatment